semaglutide cardiovascular outcomes 2025 news today and by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial Study Finds Oral Semaglutide Vastly

Efficacy and safety of novel twincretin tirzepatide, a dual GIP/GLP-1 receptor agonist, as an anti-obesity medicine in individuals without diabetes: a systematic review and meta-analysis

Tirzepatide, sold as Mounjaro and Zepbound, was not separately classified in the 2022 data and was not yet approved for weight management at that time, meaning it is not reflected in these figures

A "natural" origin of a substance tells you nothing about overall safety at a synthetic dose, by an unphysiological route, in a manufactured form whose purity is not independently verified

HSA was immobilized to the surface by pre-activation (1.0 EDC, 1.0 M NHS in PBS, pH 7.4, 7 min) followed by injection of HSA to flow cell 1 (30 g ml 1 in 10 mM NaOAc buffer, pH 5.0, twice for 7 min)

An identical semaglutide injection receives coverage when prescribed for blood sugar control but faces automatic denial when the same dose targets obesity